* Redhill biopharma announces National Cancer Institute
grant supporting Yeliva phase II hepatocellular carcinoma study
The post BRIEF-Redhill Biopharma received $1.8 mln grant from U.S. National Cancer Institute for Yeliva phase II study appeared first on NASDAQ.